World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
105
Citations
75644
World Ranking
6638
National Ranking
3517

Overview

Padmanee Sharma is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their work primarily spans the field of Medicine, with a focus on Oncology, Immunology, Pulmonary and Respiratory Medicine, Molecular Biology, and Surgery.

The scientist's research topics reflect a significant emphasis on cancer-related immunotherapy and cellular biology. Main areas of investigation include:

  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Bladder and Urothelial Cancer Treatments
  • Immunotherapy and Immune Responses
  • Immune cells in cancer
  • Immune Cell Function and Interaction
  • Single-cell and spatial transcriptomics

Padmanee Sharma has collaborated extensively with other researchers. Frequent co-authors include:

  • James P. Allison
  • Sreyashi Basu
  • Sonali Jindal
  • Sangeeta Goswami
  • Sumit K. Subudhi

The scientist has published numerous papers in several prominent venues, often contributing to high-impact journals in oncology and cancer research. Notable publication venues with multiple contributions include:

  • Journal of Clinical Oncology
  • Regular and Young Investigator Award Abstracts
  • Cancer Research
  • Clinical Cancer Research
  • bioRxiv (Cold Spring Harbor Laboratory)

Some recent papers authored or co-authored by Padmanee Sharma are:

  • "Immune checkpoint therapy-current perspectives and future directions," 2023, Cell
  • "The Next Decade of Immune Checkpoint Therapy," 2021, Cancer Discovery

Additional recent papers connected to their research include:

  • "Hallmarks of response, resistance, and toxicity to immune checkpoint blockade," 2021, Cell
  • "Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response," 2021, Science
  • "Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial," 2021, Nature Medicine

Best Publications

  • Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

    Robert J. Motzer;Bernard Escudier;David F. McDermott;Saby George

  • The future of immune checkpoint therapy

    Padmanee Sharma;James P. Allison

  • Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

    Robert J Motzer;Nizar M Tannir;David F McDermott;Osvaldo Arén Frontera

  • Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

    Padmanee Sharma;Siwen Hu-Lieskovan;Jennifer A. Wargo;Antoni Ribas

  • Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival.

    Berna C. Özdemir;Berna C. Özdemir;Tsvetelina Pentcheva-Hoang;Julienne L. Carstens;Xiaofeng Zheng

  • Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential

    Padmanee Sharma;James P. Allison

  • B cells and tertiary lymphoid structures promote immunotherapy response

    Beth A. Helmink;Sangeetha M. Reddy;Jianjun Gao;Shaojun Zhang

  • Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

    Padmanee Sharma;Margitta M. Retz;Arlene Siefker-Radtke;Ari D. Baron

  • The Human Cell Atlas

    Aviv Regev;Aviv Regev;Aviv Regev;Sarah A Teichmann;Sarah A Teichmann;Sarah A Teichmann;Eric S Lander;Eric S Lander;Eric S Lander;Ido Amit

  • PD-L1 Expression in Triple-Negative Breast Cancer

    Elizabeth A Mittendorf;Anne V Philips;Funda Meric-Bernstam;Na Qiao

  • Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

    Scott J. Antonia;José A. López-Martin;Johanna Bendell;Patrick A. Ott

  • Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy

    Jianjun Gao;Lewis Zhichang Shi;Hao Zhao;Jianfeng Chen

  • Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade

    Spencer C. Wei;Jacob H. Levine;Alexandria P. Cogdill;Yang Zhao

  • Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.

    Pei Ling Chen;Whijae Roh;Alexandre Reuben;Zachary A. Cooper

  • Hallmarks of response, resistance, and toxicity to immune checkpoint blockade.

    Golnaz Morad;Beth A. Helmink;Padmanee Sharma;Jennifer A. Wargo

  • Novel cancer immunotherapy agents with survival benefit: recent successes and next steps

    Padmanee Sharma;Klaus Wagner;Jedd D. Wolchok;James P. Allison

  • Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance

    Whijae Roh;Pei Ling Chen;Alexandre Reuben;Christine N. Spencer

  • Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities

    Ferdinandos Skoulidis;Lauren A. Byers;Lixia Diao;Vassiliki A. Papadimitrakopoulou

  • Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

    Rodabe N. Amaria;Sangeetha M. Reddy;Hussein A. Tawbi;Michael A. Davies

  • Erratum to Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival [Cancer Cell 25, 719-734; (2014)]

    Berna C. Özdemir;Tsvetelina Pentcheva-Hoang;Julienne Leigh Carstens;Xiaofeng Zheng

Frequent Co-Authors

James P. Allison
James P. Allison The University of Texas MD Anderson Cancer Center
Jennifer A. Wargo
Jennifer A. Wargo The University of Texas MD Anderson Cancer Center
Naval Daver
Naval Daver The University of Texas MD Anderson Cancer Center
Patrick Hwu
Patrick Hwu The University of Texas MD Anderson Cancer Center
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Guillermo Garcia-Manero
Guillermo Garcia-Manero The University of Texas MD Anderson Cancer Center
Farhad Ravandi
Farhad Ravandi The University of Texas MD Anderson Cancer Center
Marina Konopleva
Marina Konopleva The University of Texas MD Anderson Cancer Center
Nizar M. Tannir
Nizar M. Tannir The University of Texas MD Anderson Cancer Center
Adi Diab
Adi Diab The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in healthcare careers beyond traditional medical school, there are several flexible online degree options. These programs offer convenient and cost-effective alternatives to on-campus learning, making them popular choices for working adults and career changers.

For nursing professionals, cheapest rn to bsn program options can facilitate career advancement by allowing registered nurses to earn a Bachelor of Science in Nursing (BSN) completely online. Aspiring advanced practitioners can explore cheapest online fnp programs to become Family Nurse Practitioners without the high cost or rigid schedule of traditional routes.

Those seeking further specialization or leadership roles may be interested in online phd programs nursing, which focus on research, education, and clinical expertise. Additionally, prospective nurses or those looking to enter the field for the first time can consider online nursing programs to complete foundational studies and begin their nursing journey.

These diverse pathways make a career in medicine and healthcare more accessible, letting students study at their own pace while balancing work or family commitments.

Best Scientists Citing Padmanee Sharma

Trending Scientists